The Lancet Rheumatology
Explore clinical research, expert reviews, and comment and opinion from The Lancet Rheumatology. A voice for rheumatology specialists worldwide
Explore clinical research, expert reviews, and comment and opinion from The Lancet Rheumatology. A voice for rheumatology specialists worldwide
The markedly elevated rate of death in the first week post-release underscores an urgent need for investment in evidence-based, coordinated transitional healthcare, including treatment for…
Melatonin, a hormone primarily produced by the brain’s pineal gland, is typically secreted during darkness, aligning with the time when most people sleep. Melatonin plays…
With up to 23 years of follow-up of three large prospective cohorts of middle-aged and older men and women, self-reported melatonin supplement use was not…
Myelofibrosis is a myeloid neoplasm characterised by the presence of JAK2, CALR, or MPL mutations (with a 90% mutation frequency) and trilineage myeloid proliferation with…
TRANSFORM will recruit hundreds of thousands of men in an effort to identify the most effective screening strategies for prostate cancer. Talha Burki reports.
Launched as a public–private partnership funded by the Foundation for the National Institutes of Health, the Study to Advance Bone Mineral Density as a Regulatory…
All tested dosing regimens blocked some infections to a similar degree. Improved vaccine efficacy in participants infected during vaccination could suggest new strategies for highly…
Hydroxyurea dose escalation to MTD with dose optimisation significantly improved clinical responses and treatment outcomes, without increasing toxicities in children with sickle cell anaemia in…
Realizing Effectiveness Across Continents with Hydroxyurea (REACH) is a large prospective open-label, non-randomised trial of hydroxyurea (hydroxycarbamide) for children aged 1–10 years with sickle cell…
In patients with acute brain injury, a single ceftriaxone dose decreased the risk of early VAP. On the basis of our findings, we recommend that…